Pentixapharm Receives FDA Approval for CXCR4-Targeted Radiotheranostic Program in Blood Cancers
Key Insights
Pentixapharm Holding AG (search) received FDA approval for two Investigational New Drug applications for its CXCR4 (search)-targeted radiotheranostic program following a 30-day safety review period.
The approved applications support a Phase I/II trial evaluating PentixaFor (search) imaging and [⁷⁰Y]Y-PentixaTher (search) for targeted bone marrow conditioning in acute myeloid leukemia (search) and multiple myeloma (search) patients undergoing stem cell transplantation.
The CXCR4 (search)-directed radiotherapy approach aims to provide a less toxic alternative to conventional chemotherapy conditioning regimens, potentially benefiting over 25,000 annual stem cell transplant patients in Europe and the US.
Pentixapharm Holding AG (search) announced that the U.S. Food and Drug Administration has completed its 30-day safety review of two Investigational New Drug applications for the company's CXCR4 (search)-targeted theranostic program in hemato-oncology and confirmed that the proposed clinical study may proceed. The regulatory approval represents a significant milestone for the Berlin-based clinical-stage biotech company's innovative approach to treating blood cancers.
Dual Radiotheranostic Approach for Stem Cell Transplantation
The two IND submissions support the single PENTHERA Phase I/II protocol, which evaluates the combined use of PentixaFor (search) imaging and [⁷⁰Y]Y-PentixaTher (search) as targeted bone marrow conditioning prior to stem cell transplantation in patients with acute myeloid leukemia (search) (AML) and multiple myeloma (search) (MM). This radiotheranostic pair represents an innovative approach that combines diagnostic imaging with therapeutic intervention.
The proposed phase I/II trial is designed to confirm the suitability of CXCR4 (search)-directed radiotherapy for bone marrow conditioning in patients undergoing stem cell transplant. The study's overall aim is to complement or reduce conventional chemotherapy for AML and MM patients, potentially offering a less toxic alternative to current treatment paradigms.
Addressing Significant Medical Need
Hematopoietic stem cell transplantation remains the only potentially curative treatment option for many patients with these hematologic malignancies, yet conventional conditioning regimens rely on highly toxic chemotherapy and/or total body irradiation. Pentixapharm's CXCR4 (search)-directed radiopharmaceutical approach is designed to enable more biologically targeted conditioning while delivering antitumor activity with precision.
In Europe and the US alone, AML and MM together account for more than 25,000 stem cell transplantations annually, each requiring a conditioning regimen prior to transplant. AML and MM are serious hematologic malignancies associated with high relapse rates and ongoing unmet medical need.
Clinical Significance and Future Plans
"The U.S. INDs provide important regulatory validation of our CXCR4 (search)-targeted approach and support its advancement in the stem cell transplant setting, combining PentixaFor (search) imaging with [⁷⁰Y]Y-PentixaTher (search)," said Dirk Pleimes, CEO of Pentixapharm. "AML and MM are significant hematologic malignancies where transplantation remains central to treatment. We believe that targeted bone marrow conditioning has the potential to offer a differentiated strategy within this established chemotherapy-based paradigm."
Pleimes noted that this regulatory milestone builds on the company's ongoing investigator-initiated clinical studies in AML in Europe. The company will determine the timing of future clinical studies under the IND in accordance with its broader portfolio prioritization and resource planning.
Innovative Conditioning Strategy
Conditioning therapy prior to transplantation is designed to reduce residual disease and prepare the bone marrow for engraftment, representing an established component of the stem cell transplantation procedure. Conventional conditioning regimens typically rely on intensive chemotherapy and/or external beam radiation, which act systemically and may be associated with significant off-target toxicity.
Pentixapharm's approach represents a potential paradigm shift toward more precise, targeted conditioning methods that could reduce the substantial toxicity burden associated with current standard-of-care treatments while maintaining therapeutic efficacy in preparing patients for successful stem cell engraftment.